Fe 3 O 4 @Au loaded with PNPO-siRNA for the diagnosis and treatment of ovarian cancer

作者：Shuyi Shi, Keying Wang, Chenglong Wang, Jinwei Qiang, Yongai Li · 发表于：Nanocomposites · 年份：2025 · DOI：10.1080/20550324.2025.2565926 · 被引用次数：1 · 研究领域：Nanoparticle-Based Drug Delivery、Gold and Silver Nanoparticles Synthesis and Applications、Nanoplatforms for cancer theranostics

Aim To design and fabricate composite magnetic nanoparticles (MNPs), Fe3O4@Au(Cy5.5)-DOPE/PNPO-siRNA, for the diagnosis and treatment of ovarian cancer (adenocarcinoma cells).Materials and methods Fe3O4@Au(Cy5.5)-DOPE/PNPO-siRNA nanoparticles were synthesized using seed growth and chemical reduction methods. The fabricated Fe3O4@Au nanoparticles were systematically characterized and evaluated. For in vitro studies, the anti-tumor effects were assessed in naturally resistant SKOV3 ovarian adenocarcinoma cells. Cellular uptake, gene-silencing efficiency, and cytotoxicity assays were conducted to determine their therapeutic potential. For in vivo studies, a xenograft mouse model harboring SKOV3 tumors was established to evaluate magnetic resonance imaging (MRI) contrast enhancement and biosafety of nanoparticles. MRI was performed using T2-weighted imaging (T2WI) to monitor tumor accumulation and signal changes. The biosafety was further examined through histopathological analysis of major organs.Results We successfully designed and fabricated Fe3O4@Au composite magnetic nanoparticles (MNPs) encapsulated with surface lipids, which exhibited excellent biocompatibility and safety. These Fe3O4@Au composite MNPs effectively delivered PNPO-siRNA into SKOV3 cells, enabling both ovarian cancer treatment and MRI. In vivo MRI of SKOV3 tumor-bearing mice showed effective tumor accumulation of nanoparticles. T2WI revealed a peak signal reduction of approximately 17% at 3h post-injection (A...